Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Calyxt Expands Total Acreage with Farmers for High-Oleic Soybean Product

Posted on: 01 Mar 18

Calyxt, Inc. (NASDAQ:CLXT), a consumer-centric, food- and agriculture-focused company, today announced that the Company has expanded its total acreage with farmers across the United States for its high-oleic / no trans-fat soybean variety.

Highlights of Calyxt’s progress in preparing the high-oleic soybean launch include:

  • Calyxt has contracted over 10,000 acres with 50 farmers in the Midwest.
  • Overall, these growers collectively farm over 100,000 acres, half of which are expected to produce soybeans. Twenty percent of the soybeans that are anticipated to be planted consist of Calyxt’s high-oleic variety.
  • Calyxt’s recent partnership with Farmer’s Business Network, Inc. (FBN) added to the distribution and grower base of Calyxt’s identity-preserved high-oleic soybeans across the upper Midwest region, including South Dakota and Minnesota.

“The vast expansion of Calyxt’s high-oleic soybean variety, along with our strong grower retention year-over-year, signifies important advancements in our product offering as we prepare for the commercial launch of the soybeans later this year,” said Federico Tripodi, Calyxt CEO. “Calyxt is at the forefront of history when it comes to bringing to market crops with healthier characteristics and improved traceability that consumers want and need, and continuing to cultivate a dedicated, high-quality grower base in the upper Midwest region is key to our success.”

The high-oleic / low-saturated fat oil from this new variety of soybeans is designed to eliminate the need for hydrogenation, a process that improves heat stability and shelf life of conventional soybean oil. The process of hydrogenation contributes to the production of trans-fatty acids, which, when consumed, raises low-density lipoprotein, or LDL, and cholesterol levels, as well as contributes to cardiovascular diseases. The FDA has declared trans fats not generally recognized as safe (GRAS), and human food must no longer contain partially hydrogenated oils by June 18, 2018.

In mid-2015, Calyxt received a letter from the USDA confirming that the Company’s high-oleic soybean variety is non-regulated, as the product contains no foreign DNA.

About Calyxt
Calyxt, Inc. is a consumer-centric, food- and agriculture-focused company. Calyxt is pioneering a paradigm shift to deliver healthier food ingredients, such as healthier oils and high fiber wheat, for consumers and crop traits that benefit the environment and reduce pesticide applications, such as disease tolerance, for farmers. Calyxt develops non-transgenic crops leveraging processes that occur in nature by combining its leading gene-editing technology and technical expertise with its innovative commercial strategy. Calyxt is located in Minneapolis-St. Paul, MN, and is listed on the Nasdaq market (ticker: CLXT).

For further information please visit our website:
Calyxt™ and the corporate logo are trademarks owned by Calyxt, Inc.
TALEN® is a registered trademark owned by the Cellectis Group.

Calyxt Forward-Looking Statements

This communication contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. In some cases, you can identify these statements by forward-looking words such as “may,” “might,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or “continue,” the negative of these terms and other comparable terminology. These forward-looking statements, which are subject to risks, uncertainties and assumptions about us, may include projections of our future financial performance, our anticipated growth strategies and anticipated trends in our business. These statements are only predictions based on our current expectations and projections about future events. There are important factors that could cause our actual results, level of activity, performance or achievements to differ materially from the results, level of activity, performance or achievements expressed or implied by the forward-looking statements, including those factors discussed under the caption entitled “Risk Factors” in our registration statement on Form S-1, along with our other filings with the U.S. Securities and Exchange Commission. We do not assume any obligation to publicly provide revisions or updates to any forward-looking statements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by securities and other applicable laws.

View source version on

Business Wire

Last updated on: 01/03/2018

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.